A/APublished research associates this genotype with typical/baseline likelihood of Serum bilirubin levels in metabolic syndrome — no copies of the reported risk allele.
A/GPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Serum bilirubin levels in metabolic syndrome.
G/GPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Serum bilirubin levels in metabolic syndrome compared to the general population.
rs929596 is a single position in the genome, in or near the UGT1A1 gene. Published research associates it with serum bilirubin levels in metabolic syndrome. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
What conditions is rs929596 linked to?
On MyGeneLog this position is linked to Metabolic Syndrome. The research behind each link, and its sources, are set out on that condition page.
Does rs929596 affect how medicines work?
UGT1A1 carries pharmacogenomic findings for Atazanavir, Irinotecan. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs929596 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs929596 come from?
GWAS Catalog, Nutrients 2019, PMID:30621171. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.